Intercepting the Siglec-mediated interactions in cancer and inflammation (SIGINT)

Description of the granted funding

One of the major scopes of the project is to shed light on the “dark matter of the biological universe”, the glycans, recognized by Sialic acid-binding immunoglobulin (Ig)-like lectin 9 (Siglec-9) in inflammation and cancer. Siglec-9 regulates the innate and adaptive immune systems by recognizing sialic acids on the surface sialoglycans of its binding partners. These interactions have a role in many infectious diseases, inflammation, neurodegeneration, autoimmune diseases, and cancer, which makes the sialic acid–Siglec axis an emerging target to prevent or affect these diseases. The project aims to unveil the multivalent Siglec-9 interactions and design novel inhibitors that block all Siglec-9-mediated interactions in inflammation and cancer. The designed inhibitors will serve as a starting point for the development of anti-inflammatory and anti-cancer agents.
Show more

Starting year

2021

End year

2023

Granted funding

Tiina Salminen Orcid -palvelun logo
250 000 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

340066

Fields of science

Biochemistry, cell and molecular biology

Research fields

Biokemia, biofysiikka

Identified topics

cancer